NSCEB Warns China’s Growing Control Over Drug Supply Risks US Access

3 min readSources: Axios

The NSCEB warns about China's increasing control over the drug supply chain and the risks to US medicine access.

Why it matters: This exposes legal and compliance teams to heightened regulatory and geopolitical challenges in pharmaceutical supply chains. National security concerns now intersect with corporate risk management and contract negotiations.

  • On November 19, 2026, NSCEB warned about China's expanding control over the pharmaceutical supply chain.
  • Since early 2023, Western pharmaceutical firms entered 57 licensing deals transferring expertise to Chinese companies.
  • China supplies a large share of active pharmaceutical ingredients (APIs), essential medicine components, with recurring quality issues reported.
  • In 2019, US imports of pharmaceuticals and medical products from China totaled $20.7 billion, accounting for 9.2% of all US imports.

On November 19, 2026, the National Security Commission on Emerging Biotechnology (NSCEB) issued a warning about China's growing dominance over the global pharmaceutical supply chain, which could limit US access to vital medicines.

The NSCEB's report documented 57 licensing agreements since early 2023, where Western pharmaceutical companies have transferred financial resources and technical expertise to Chinese firms, accelerating China's pharmaceutical capabilities.

Active pharmaceutical ingredients (APIs) are the chemically active components of medications. China is a major global supplier of APIs, integral to drugs distributed across North America, Europe, and Asia. Industry analyses have revealed concerns following inspections at Chinese manufacturing sites, highlighting deficiencies in quality controls, documentation, and manufacturing protocols.

According to a 2019 government report, US imports of pharmaceuticals and medical products from China were valued at $20.7 billion, representing 9.2% of total US imports that year, illustrating the substantial reliance on Chinese pharmaceutical production.

Caitlin Frazer, NSCEB Executive Director, stated on November 19, 2026, that "China's biotechnology strategy is a decades-long effort to gain economic and geopolitical advantage." Former US National Economic Council Director Gary Cohn added, "If you're the Chinese and you want to really just destroy us, just stop sending us antibiotics," framing the supply chain vulnerabilities within broader geopolitical risks.

Independent analyses by industry watchdogs and the U.S. Food and Drug Administration corroborate concerns regarding quality issues in Chinese pharmaceutical manufacturing. This underscores the multifaceted challenges legal teams face in managing contracts and compliance amid shifting geopolitical landscapes.

By the numbers:

  • 57 — licensing deals transferring pharmaceutical expertise from Western firms to China since early 2023
  • $20.7 billion — value of US pharmaceutical imports from China in 2019
  • 9.2% — share of total US imports accounted for by pharmaceuticals and medical products from China in 2019

Yes, but: While China is a major supplier of APIs, some pharma firms are diversifying supply chains to reduce risks and improve quality assurance.

What's next: Legal and compliance teams should monitor regulatory updates and supply chain disclosures as geopolitical tensions influence pharmaceutical trade policies.